Publication:
The effects of the renin-angiotensin-aldosterone system blockers on serum ischemia-modified albumin levels in autosomal dominant polycystic kidney disease

dc.contributor.authorErmurat, Selime
dc.contributor.authorGüllülü, Mustafa
dc.contributor.authorSarandöl, Emre
dc.contributor.buuauthorGÜLLÜLÜ, MUSTAFA
dc.contributor.buuauthorSARANDÖL, EMRE
dc.contributor.departmentBursa Uludağ Üniversitesi/Tıp Fakültesi/Nefroloji Anabilim Dalı.
dc.contributor.departmentBursa Uludağ Üniversitesi/Tıp Fakültesi/Klinik Biyokimya Anabilim Dalı.
dc.contributor.researcheridJGS-9425-2023
dc.contributor.researcheridDXM-3644-2022
dc.date.accessioned2024-09-18T13:18:08Z
dc.date.available2024-09-18T13:18:08Z
dc.date.issued2022-01-23
dc.description.abstractBackground Among one of the common hereditary causes of chronic kidney disease is autosomal-dominant polycystic kidney disease (ADPKD), and its incidence rate is reported as one between 500 and 1.000 individuals. The most common complications of ADPKD are hypertension (HT) and end-stage renal disease (ESRD). HT occurring in the early stage of ADPKD leads to deteriorations in renal function. Aims It was aimed to investigate the ischemia-modified albumin (IMA) levels and the effect of renin-angiotensin-aldosterone system (RAAS) blockers on serum IMA levels in patients with ADPKD. Methods One hundred and fifteen patients were included as ADPKD (n = 50), HT (n = 35), and healthy control (HC) groups (n = 30). Patients with ADPKD and HT were divided into two subgroups as RAAS blocker-users and non-users. Results Serum IMA levels were detected as 0.42 (0.17-0.80) in ADPKD and 0.28 (0.04-0.51) in HT and 0.36 (0.22-0.56) in HC groups as absorbance units (ABSU), and the highest serum IMA level was seen in Group ADPKD. Serum IMA levels were 0.33 +/- 0.14 in RAAS blocker-users and 0.41 +/- 0.11 ABSU in non-users with ADPKD. Serum IMA levels were witnessed to be significantly lower in RAAS blocker-users in Groups ADPKD (p = 0.038) and HT (p = 0.004), compared to non-users. Given basal and 6-month values of those with ADPKD, the levels of serum IMA within 6 months were significantly lower (p = 0.002). Conclusions We consider that serum IM levels should be assessed in oxidative stress (OS)-related conditions, such as ADPKD, and RAAS blockers may be effective in reducing serum IMA levels in ADPKD and HT patients.
dc.identifier.doi10.1007/s11845-022-02925-y
dc.identifier.endpage2783
dc.identifier.issn0021-1265
dc.identifier.issue6
dc.identifier.startpage2777
dc.identifier.urihttps://doi.org/10.1007/s11845-022-02925-y
dc.identifier.urihttps://link.springer.com/article/10.1007/s11845-022-02925-y
dc.identifier.urihttps://hdl.handle.net/11452/44906
dc.identifier.volume191
dc.identifier.wos000745754300001
dc.indexed.wosWOS.SCI
dc.language.isoen
dc.publisherSpringer London Ltd
dc.relation.journalIrish Journal of Medical Science
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectOxidative stress
dc.subjectEndothelial dysfunction
dc.subjectAsymmetric dimethylarginine
dc.subjectInsulin-resistance
dc.subjectProgression
dc.subjectBlockade
dc.subjectDamage
dc.subjectAutosomal dominant polycystic kidney disease
dc.subjectIschemia modified albumin
dc.subjectOxidative stress
dc.subjectRenin-angiotensin-aldosterone blockade
dc.subjectGeneral & internal medicine
dc.titleThe effects of the renin-angiotensin-aldosterone system blockers on serum ischemia-modified albumin levels in autosomal dominant polycystic kidney disease
dc.typeArticle
dspace.entity.typePublication
relation.isAuthorOfPublication47f5ec68-c479-4f62-9aed-37ba604a689c
relation.isAuthorOfPublication9529fb52-20cd-4fb3-9767-19121683aa62
relation.isAuthorOfPublication.latestForDiscovery47f5ec68-c479-4f62-9aed-37ba604a689c

Files

Collections